Free shipping on orders $250+ Tracked shipping Bundle pricing — 2 of same / 5% · 3+ of same / 9% ≥ 99% purity Third-party lab tested Researcher-only catalog Free shipping on orders $250+ Tracked shipping Bundle pricing — 2 of same / 5% · 3+ of same / 9% ≥ 99% purity Third-party lab tested Researcher-only catalog

Selank: Anxiolytic Peptide Research Guide

Research Use Only. This page is provided for educational and analytical-reference purposes. Loft Purity products are sold strictly as reference materials for in-vitro laboratory work and are not intended for human or animal use, diagnosis, therapy, or any consumer application.

Summary

Selank is a synthetic heptapeptide derived from the naturally occurring immunomodulatory tetrapeptide tuftsin, with two additional stabilizing residues that extend its functional half-life. It is studied in nootropic and anxiolytic-pathway literature, particularly in Russian and Eastern European research groups.

Overview

Selank was developed at the Institute of Molecular Genetics in Moscow by extending the tuftsin sequence (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro tripeptide that confers resistance to proteolytic degradation. It is studied in literature on enkephalin signaling, GABAergic pathways, and stress-response models in animal subjects.

Research Background

Selank was developed by the laboratory of Vladimir Mikhailovich Kovalzon and colleagues in the 1990s. The compound has been studied extensively by Kost, Sollertinskaya, and others in Russian-language literature, with English-language reviews summarizing the anxiolytic-pathway and neurotrophic findings.

Mechanisms Studied

Mechanistic interest centers on modulation of enkephalin levels, GABAergic signaling, BDNF expression, and stress-response markers in animal-model systems. Selank is also studied as part of the broader literature on short bioactive peptides derived from longer endogenous sequences.

Published Research Summary

Kost et al. (2001) review the pharmacology of selank as an anxiolytic-pathway research peptide. Kolomin et al. (2013) report gene-expression effects in rat-brain models. Sollertinskaya and Shamakina (2018) summarize comparative work with related short peptides.

Quality & Verification

For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.

References & Published Research

← Back to Education Hub